Pharmaceutical Executive Search for Quality, Operations and Site Leaders
Retained search for the leaders who answer for your quality unit, your production floor and the site itself.
How many people in the country could actually run your site?
Pharmaceutical executive search is a retained search for the leaders who run a drug maker’s quality unit, manufacturing operations and sites. KORE1 maps the national pool for the seat and presents three to five assessed finalists.
Last updated: October 2, 2026
Fewer than you’d guess. Federal wage data counts 510 chief executive jobs across all of U.S. pharmaceutical and medicine manufacturing, an industry that employs 348,780 people. That’s the whole country.
A pool that small doesn’t answer job ads. It gets mapped, name by name, and approached quietly. KORE1’s executive recruiters do that in every industry we serve, and I do it in this one.
I opened KORE1’s Scientific Division at the end of 2018 and led it, and I’ve built a business of my own since. So I know the seat from the inside.
- This desk
- Executive seats only. Heads and vice presidents of quality, site heads and plant general managers, manufacturing and technical operations leaders, and the scientific leaders who own the laboratories.
- Routed elsewhere
- Manager and specialist seats go to our pharmaceutical recruiters, research and therapeutic-area searches to our biotech recruiters, contract crews to pharmaceutical staffing, and finance or technology chiefs to the wider executive search practice.
Leadership search is one desk in KORE1’s life sciences staffing practice. The mechanics of a retained engagement, stage by stage, are laid out in our guide to how executive search works, so this page sticks to what changes when the seat is at a drug maker. Quite a lot does. KORE1’s 92% twelve-month retention figure includes these searches.
Pharmaceutical Executive Search Starts With the Chart the Rules Ask For
European manufacturing rules make a drug manufacturer keep an organisation chart of its key personnel. Here is that chart with two things added, the rule that names each seat and how many U.S. jobs like it exist.
Key personnel, as the rules name them
U.S. pharma manufacturing · BLS OEWS, May 2025
Site head
President, general manager, plant manager
- Named in
- United States v. Park, 1975
- U.S. jobs
- 510 chief executives, 7,370 general and operations managers
Head of production
Manufacturing, technical operations
- Named in
- EU GMP Chapter 2, clause 2.5
- U.S. jobs
- Shared count with quality
Independent from each other8,080 U.S. jobs, counted as one occupation
Head of quality
Quality unit, release authority
- Named in
- 21 CFR 211.22
- U.S. jobs
- Shared count with production
Qualified Person
Only if you release batches into the EU
- Named in
- Directive 2001/83/EC, Article 51
- U.S. jobs
- Not counted separately
Head of laboratories
Analytical development, quality control labs
- Named in
- No rule. Your filing leans on it.
- U.S. jobs
- 5,430 natural sciences managers
One wall, one shared headcount. The rules split production from quality. The wage survey counts them together.
Read the wall first. Europe’s good manufacturing practice (GMP) rules say the heads of production and quality control “must be independent from each other,” in Chapter 2 of the EU GMP guide, and the U.S. rule at 21 CFR 211.22 gives the quality unit authority to approve or reject every batch. Two seats, and neither reports to the other.
Now the number under it. The federal wage survey files production managers and quality control systems managers under one occupation, 8,080 jobs in pharma manufacturing, so the people on both sides of that wall come out of a single shared count, and somewhere inside it is the short list of leaders who have run a quality unit through an inspection and would do it again for you. That’s the pool. All of it.
Laboratory and scientific leaders are counted on their own line, and the top seat is the thinnest of all. Can a research lab leader step into a plant? Sometimes. My piece on how lab experience carries into GMP manufacturing covers when.
Every count here is a May 2025 national estimate for pharmaceutical and medicine manufacturing, taken from the OEWS wage survey that BLS publishes.
The Leader’s Name Is on More Than the Door
Most executives can be fired. A pharma executive can be prosecuted. That’s the plain reading of United States v. Park, a 1975 Supreme Court case that still shapes how federal drug law is enforced against the people at the top of a company.
The Court said an officer answers for a violation when that officer had, by reason of position, “responsibility and authority either to prevent in the first instance, or promptly to correct” it, and didn’t. Proof of knowing isn’t part of the test. The authority is.
Good candidates know this cold. So their first questions to me are about authority, and mine to them are too.
- Tell me about a batch, a launch or a shipment you stopped. Who pushed back?
- Which inspections did you host as the senior person in the room, and what did the agency write down?
- What did you inherit?
- Have you ever turned down a seat because of who it reported to?
None of those has a right answer. Each has a true one, and you can hear the difference. It’s usually in the pause.
What Pharmaceutical Executive Search Firms Should Check Before You Meet Anyone
References come last in most searches. Here, two checks come first. Both are public, and neither appears in the usual questions for vetting an executive search firm.
FDA keeps a debarment list. Under 21 U.S.C. 335a, a debarred person can’t provide “services in any capacity” to a company with an approved or pending drug application, and every application has to certify that nobody on the list was used.
Any capacity. That includes the corner office.
The second is the exclusion list kept by the HHS Office of Inspector General, which says anyone who hires a person on it may face civil penalties. It matters most when Medicare or Medicaid pays for what you make. We search both lists before you see a name. Takes a minute.
Then the conversation. On a confidential search the candidate doesn’t know your company yet, and I like it that way, because the first call ends up being about what they want from the next ten years instead of a pitch they can nod along to. I ask the way a friend would. Leaders at this level have options, and an honest answer about what would make them move is worth more to you than a polished one.
510
chief executive jobs in U.S. pharma manufacturing
48,210
management jobs of every kind in the same industry
$369,510
median yearly pay for those chief executives
92%
twelve-month retention across KORE1 placements
Sources: BLS OEWS industry profile, May 2025 estimates, NAICS 3254. KORE1 retention data.
Leadership Seats Our Pharmaceutical Executive Search Covers
The tag on each card names what that leader signs. At a small company one person may hold two of these for a while. Never production and quality together.
Signs the release
Head or VP of quality
Owns the quality unit, the release decision and the answer when an inspector asks who approved it.
Signs for the site
Site head or plant general manager
Runs the building, the budget and the people, and receives the inspection findings on the firm’s behalf.
Signs the batch record
VP of manufacturing or technical operations
Leads production, technology transfer and supply, often across your own plant and a contract manufacturer’s.
Signs the data
Head of analytical or QC laboratories
Scientific leaders who own the methods, the stability program and the chemistry section of your filing.
Most of these run as retained or engaged searches, because the people you want are employed, careful and not reading job boards. A full retained search usually takes 90 to 120 days from scoping to a signed offer. Faster is possible. Rushed isn’t.
Not sure the company needs the seat yet? Start with my guide to the point where a small drug maker should hire a director of quality, and for pay one level down, see the quality manager salary guide. Outsourced manufacturing changes the brief as well. A leader who has only ever run their own plant manages an outside manufacturing partner, a CDMO in the trade’s shorthand, very differently from one who has worked on both ends of that contract, which is why CDMO experience gets its own line on every scorecard we write.
Need someone in the chair while the search runs? An interim leader on a contract can hold it. Director-level roles in a market with a deeper bench often fit a standard direct hire search instead, and if you’re still choosing between models, our comparison of retained and contingency search walks through what each one costs and what each one gets you.
Common Questions
What is pharmaceutical executive search?
It’s a retained search for the senior leaders of a drug maker. Quality, manufacturing, site and laboratory heads. KORE1 maps who holds those jobs today, approaches them quietly and brings you a short slate.
How long does a pharmaceutical executive search take?
90 to 120 days is typical for a retained search, from scoping to a signed offer. Notice periods come on top of that. Leaders at this level usually owe their current employer a real handover, and a candidate willing to walk out on one company’s release schedule would be willing to walk out on yours, so we treat a long notice period as a good sign.
What do pharmaceutical executive search firms charge?
Expect a fee between 20% and 35%, figured on first-year base pay. Retained searches stage it across the engagement. Ask what happens if the hire leaves, and get the replacement terms in writing before the search opens.
Can you replace a head of quality who is still in the seat?
Yes, and quietly. Your company name stays out of the outreach until you say otherwise. One caution from the regulated side, though. A quality unit can’t sit empty, so we plan the handover date and any interim cover before the first call goes out, which is a lot easier than planning it the week after an offer is signed.
Do you check the FDA debarment list?
Every finalist, before you see the name. A debarred person can’t provide services in any capacity to a company with an approved or pending drug application. We search the federal health care exclusion list as well.
Can a leader from a big drug maker succeed at a small one?
Sometimes, if they still like doing the work themselves. At a small company the head of quality writes procedures, sits in on investigations and hosts the inspection, with no department underneath to hand things to. Ask what they did last month. Not what their team did.
Start the Search Quietly
Tell me which seat is open, who knows about it and when you need a signed offer. I’ll tell you how big the pool really is, and who in it would pick up the phone.
Let’s Connect →Expert in finding you the right talent, right away.
Prefer LinkedIn? Message Dave Manchester
